Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$49.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Amarantus Bioscience Holdings Inc Announces Positive Analytical Performance Data for LymPro Test For Alzheimer's Disease


Monday, 14 Oct 2013 12:09pm EDT 

Amarantus Bioscience Holdings, Inc announced positive analytical performance data for the LymPro Test, the Company's blood test for Alzheimer's disease. The data produced begins the process necessary to establish long-term analytical performance to support commercial launch in the 2nd half of 2014, and allows the Company to start focusing on the clinical performance data package the Company believes will be required for a product launch. LymPro diagnoses Alzheimer's disease by evaluating the response of peripheral blood lymphocytes (PBLs), derived from whole blood, to a mitogenic stimulation that initiates activation of the cell-cycle. In healthy individuals, when PBLs are stimulated with pokeweed mitogen (PWM) or phytohaemagglutinin (PHA), the biomarker CD69 is increased as a response to the inappropriate initiation of the cell-cycle process that is subsequently halted by healthy cellular mechanisms. However, in patients with Alzheimer's disease, the biomarker CD69 is not increased as PBLs enter the cell cycle inappropriately and are not halted due to dysfunctional cellular mechanisms that are hypothesized to be at the root of Alzheimer's disease. 

Company Quote

0.0453
-0.0037 -7.55%
24 Apr 2015